What is vesugen? The KED peptide and what the studies show

What is vesugen?

Vesugen is a peptide only three amino acids long: lysine, glutamic acid and aspartic acid, written KED or Lys-Glu-Asp. Its developers in St Petersburg describe it as a vasoprotective peptide found in a protein complex taken from calf blood vessels, and it belongs to the family of short peptides sold as bioregulators.

Vesugen is the name attached to one of the shortest peptides on the market: three amino acids, lysine, glutamic acid and aspartic acid, joined in a chain. In the research literature it is usually written as KED, the one-letter codes for those three, or as Lys-Glu-Asp. A 2021 paper from the group that developed it states its identity in a single line: the KED peptide, Vesugen, is a vasoprotective peptide found in a polypeptide complex obtained from cattle vessels [1]. Vasoprotective simply means protective of blood vessels.

That origin story is the key to everything else on this page. A 2024 paper from the same St Petersburg circle explains that KED was one of three short peptides isolated from protein complexes of calf tissue: KED from the vessels, a second peptide from the cerebral cortex, and a third from the pineal gland [2]. The third one is the better known Epitalon. The idea in each case was to find a tiny, defined piece of a tissue extract that could be made in a laboratory and was said to act on the tissue it came from. The same paper sorts brain-targeted products into two groups, mixtures extracted from cattle or pig brain such as Cerebrolysin, and short synthetic peptides, and it names vesugen in the second group alongside semax, cortagen and pinealon [2].

So vesugen sits in the family usually called peptide bioregulators. A 2021 systematic review by its developers lists it in a table of short peptides with a long list of jobs attached: regulation of cardiovascular system function, protection of nerve cells, and activation of stem cells and of skin fibroblasts [3]. If you have read our explainer on whether peptide bioregulators work, the pattern will be familiar: one small molecule, many claimed effects, and a research record with a single address. The 2021 paper lists the first author's affiliation as the Saint Petersburg Institute of Bioregulation and Gerontology [1].

The blood vessel claim: what the cell studies found

The vascular case for vesugen rests on cell cultures. In lining cells from blood vessels, the developers report that it raised a marker of cell division, normalised endothelin-1 in cells modelled on atherosclerosis, and raised the enzyme SIRT1. These are laboratory results; none is a measurement in a human artery.

Vesugen is sold first as a peptide for blood vessels, so that is the place to start. Every result in this section comes from cells grown in dishes or from computer modelling, mostly using endothelial cells, the single layer of cells that lines the inside of every blood vessel and that goes wrong early in atherosclerosis.

A 2014 study reported that vesugen stimulated Ki-67, a protein cells make when they are preparing to divide, which falls with age, both in tissue cultures taken from young and old animals and in cultures of vascular endothelial cells [4]. The same paper then used molecular docking, a computer simulation of how two molecules might fit together, to propose that vesugen binds the promoter region of the gene that codes for Ki-67 [4]. That is the core of the developers' mechanism: the claim that a tripeptide reaches the cell nucleus and switches particular genes up or down. Their 2021 review describes this as working through specific DNA–peptide interactions and/or binding to histones, the proteins DNA is wrapped around [3].

A 2016 study went closer to disease. It compared endothelial cells in normal, atherosclerotic and restenotic conditions in the laboratory, restenosis being the re-narrowing of an artery after it has been opened [5]. The authors report that KED normalised the expression of endothelin-1, a signalling molecule that constricts vessels and rises in atherosclerosis and restenosis, and that it increased SIRT1, an enzyme they connect to DNA repair [5].

A 2022 review by the same group pulls these threads together. It says KED activated markers of endothelial function including Ki67, Cx43 and VEGF and reduced p53, a brake on cell division, as endothelial cells aged in culture [6]. From there the review makes its biggest step: that stimulating endothelial cell division may indicate an ability to prevent the development of atherosclerosis at its initial stage [6].

Notice the word may. Making a cell divide in a dish is a long way from preventing a plaque in a person, and more division is not automatically good news in a blood vessel. Read these as hypotheses the developers have built from cell work, not as evidence that vesugen protects arteries.

The brain claim: mice and neurons in a dish

The strongest single study of vesugen is a 2021 experiment in mice bred to develop Alzheimer-like changes. KED preserved some types of dendritic spine, the tiny connection points between neurons, but the effect differed between males and females and its effect on how strongly the connections responded did not reach statistical significance.

Although vesugen is described as a vascular peptide, its most detailed recent research is about the brain. This is the best evidence on the page, so it is worth reading slowly.

The key paper used 5xFAD mice, a strain engineered to develop the amyloid build-up seen in Alzheimer's disease. The animals received KED by daily injection into the abdominal cavity from 2 to 4 months of age [1]. The researchers then counted dendritic spines, the small protrusions on neurons where connections with other neurons form, in a memory-related part of the brain. Their headline is that KED and a sister peptide prevented the loss of these spines [1].

The detail is more mixed than the headline. In male mice, KED raised overall spine density by 22% compared with untreated Alzheimer-model males [1]. In females, it restored one type of spine, the thin ones, but not the mushroom-shaped ones that are usually linked to stable memory [1]. And on long-term potentiation, the electrical measure of how well connections strengthen with use, the authors report a positive trend that did not reach statistical significance [1]. That is an honest paper reporting a partial result, and it is in mice.

A 2024 study took a different route. It turned skin cells from elderly donors directly into neurons, a model of an ageing human neuron, and added three peptides [2]. With KED, the number of primary dendrites rose by 32% and their total length by 42% [2]. A 2019 study in human stem cells from the ligament around the teeth found that KED increased nestin, a protein made by early nerve cell precursors [7].

The developers' own review of this work states that oral use of KED improved memory and attention in elderly people with functional nervous system disorders, and it closes by calling further animal studies of KED in Alzheimer's disease very important [8]. That is a fair summary of where the brain claim stands: interesting cell and mouse signals, and a human claim this page could not find tested in a controlled trial.

Has vesugen been tested in people?

Only in small reports. The human studies this page could read are three short abstracts in a Russian gerontology journal: 32 adults aged 41 to 83 with brain and other chronic conditions, 41 men with erectile dysfunction, and a study of lorry drivers. None of the three abstracts describes a placebo group or random allocation.

A 2022 review by the developers says the anti-atherosclerotic effect of KED was revealed when it was taken by mouth in older patients [6]. Here is the human record this page was able to find and read. All three reports were published in Advances in Gerontology, and each is available to us only as a short English abstract.

The first, from 2015, studied vesugen and a related peptide, pinealon, in people with several chronic illnesses and an organic brain syndrome in remission. The abstract reports 32 people (18 men, 12 women) aged 41 to 83 [10]. Those two subgroups add up to thirty, not thirty-two, and the abstract does not explain the gap. The authors report that vesugen showed a more visible effect on biological age markers than pinealon [10]. They also report two findings that rarely make it onto a product page: a prooxidant effect, the opposite of the antioxidant action often advertised, and a fall in CD34+ blood stem cells that they themselves describe as significant inhibition of blood cell formation [10].

The second, from 2014, describes vezugen, an alternative spelling, given on its own to 41 patients with erectile dysfunction caused by poor blood flow, and reports that blood flow through the main penile artery improved after treatment [11]. The abstract does not mention a comparison group, so it cannot separate the peptide from time, attention or other treatment. Oddly, the paper's indexed title refers to arterial insufficiency in the legs while its abstract describes erectile dysfunction, which is one more reason to want the full text before leaning on it.

The third, from 2012, compared the mental health of 150 lorry drivers with 150 metal craftsmen and reports that peptide bioregulators improved the drivers' psychological measures, with the best effect when pinealon and vezugen were combined [12]. The abstract does not say how many drivers received the peptides or what they were compared against.

A search of the US clinical trials registry, ClinicalTrials.gov, for vesugen or vezugen returned no registered study when this page was written. That does not prove no other human data exists, especially in Russian, but it means no trial of vesugen is on that public register for anyone to check.

Where the evidence is weak

Three weaknesses stand out. Almost all of the research comes from one network of laboratories. Some results point in opposite directions, with KED reported to both stimulate and suppress cell division and the same gene. And nothing here shows how much of a swallowed three-amino-acid peptide reaches the blood intact.

The first weakness is origin. Every laboratory, animal and review paper cited on this page lists N. S. Linkova among its authors, and all but one also list Vladimir Khavinson, the founder of the bioregulator programme. That is not evidence of anything wrong. It is the ordinary reason science asks for replication by people with no stake in the result, and for vesugen this page could not find any.

The second weakness is consistency. A 2020 study in human bone marrow stem cells found that KED inhibited the FOXO1 gene by 1.6 to 2.3 fold, and that its effect on a second gene, TNKS2, flipped direction between two models of the same ageing cells, inhibited in one and stimulated in the other [9]. A 2019 paper from the same network notes that KED had previously decreased stem cell proliferation while stimulating the proliferation of thymus cells and skin fibroblasts, and that an inhibitory effect on embryonic and immortalised cells had been read as possible anti-tumour activity [7]. Yet the vascular papers above present increased cell division as the benefit. A molecule can genuinely behave differently in different cells, but a theory that welcomes both outcomes is hard to test.

The range of claimed effects is itself a signal. One 2012 paper reports that KED stimulated cell renewal in cultured pineal tissue and also modulated associative learning in honey bees [13]. Breadth like that is common in early-stage research programmes and rare in compounds that end up as medicines.

The third weakness is the route. The human reports and reviews describe vesugen being taken by mouth, yet a three-amino-acid peptide is exactly the kind of molecule the digestive system breaks down for food. None of the sources on this page measures vesugen in the blood after it is swallowed, so whether an oral dose reaches blood vessels or the brain intact is an open question rather than an answered one. If you want to understand why that matters for every peptide, our free module on how peptides work explains the barriers a swallowed peptide has to get past.

Is vesugen safe, and is it legal?

Nobody can say from the published record. No safety study of vesugen in people was found, the one human abstract that looked at blood markers reported a prooxidant effect and suppressed blood stem cells, and vesugen is not an approved medicine in the United States, where products like it are sold outside drug regulation.

Safety is the question most people arrive with, and it is the one the literature answers least. The only human report on this page that looked at safety-related blood measures is the 2015 study of 32 adults aged 41 to 83 [10]. Its authors concluded that vesugen and pinealon did not change chromatin condensation, so they called them safe on a nuclear genetic level [10]. In the same abstract they report a prooxidant effect and a significant inhibition of blood cell formation [10]. Both findings come from a small study with no described control group, so neither is a verdict. Together they show that the honest answer to whether vesugen is safe is that it has not been properly studied.

On the legal side, vesugen is not an FDA-approved drug, and no registered clinical trial of it appears on ClinicalTrials.gov. Anything sold online under its name is not a regulated medicine, which means no regulator has checked that what is in the capsule or vial matches the label. That gap applies to the whole bioregulator category, not just this one peptide.

The practical takeaway is simple. Vesugen is a real molecule with a real body of laboratory work behind it, and a human evidence base too thin to tell anyone what it does in a person. If you have heart or blood vessel disease, the treatments with tested outcomes are the ones your clinician can prescribe, and anything you are considering on top of them belongs in that conversation.